Exagen to Participate in Canaccord Genuity 13th Annual MedTech & Diagnostics Forum on November 21, 2019

Published

SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that Ron Rocca, CEO of Exagen, will be participating in the 13th Annual Canaccord Genuity Medical Technology and Diagnostics Forum on Thursday, November 21 in New York City. Mr. Rocca’s presentation will take place at 11:30 a.m. EST

A live audio webcast of the Canaccord Genuity presentation will be available online from the investor relations section of the Exagen website at https://investors.exagen.com/ or through the following link: http://wsw.com/webcast/canaccord37/xgn/

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis.

CONTACTS:

InvestorsWestwicke Partners Mike CavanaughMike.Cavanaugh@westwicke.com646.677.1838 MediaExagen Inc. Kamal AdawiKAdawi@exagen.com760.477.5514

Exagen_Full_CMYK_Print.jpg

Exagen, Inc.

In This Story

XGN